Pancreatic Cancer Therapy Market 2020 In-depth Research on Market Size, Share | Revenue, Trends, Price, Gross Margin, an

Posted by Shahbaz on October 14th, 2022

Rise in number of patients suffering with pancreatic cancer is driving the market for pancreatic cancer therapy over the forecast period

According to The Insight Partners market research study titled ‘Pancreatic Cancer Therapy Market - Global Analysis and Forecasts By Type, Therapy, the global pancreatic cancer therapy market is expected to reach US$ 4,056.4 Mn in 2025 from US$ 2,011.2 Mn in 2017. The market is estimated to grow with a CAGR of 8.1% from 2018-2025. The report highlights the trends prevalent in the global pancreatic cancer therapy market and the factors driving the market along with those that act as deterrents to its growth.

Global pancreatic cancer therapy market, based on the type was segmented into endocrine pancreatic cancer and exocrine pancreatic cancer. In 2017, the exocrine pancreatic cancer segment held the largest share of the market, by type. The exocrine pancreatic cancer segment is expected to grow at the fastest rate during the coming years as this cancer is majorly occurring cancer type among the two and thus is expected to have massive patient pool over the forecast years.

Explore Premium Report on Pancreatic Cancer Therapy Market at: https://www.theinsightpartners.com/sample/TIPMD00002009/

The market for pancreatic cancer therapy is expected to grow due to rise in number of patients suffering with pancreatic cancer, increasing healthcare expenditures for pancreatic drugs, and increase in number of therapies launched in the market are boosting the market over the years. In addition, development of efficient therapy for pancreatic cancer treatment are likely to have a positive impact on the growth of the pancreatic cancer therapy market in the coming years.

The major players operating in the pancreatic cancer therapy market include Eli Lilly and Company, F. Hoffmann-La Roche AG, Celgene Corporation, Amgen Inc., Novartis AG, Pharmacyte Biotech Inc., Clovis Oncology, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Merck & Co., Inc. among others. For instance, in May 2018, Eli Lilly and Company acquired AMRO BioSciences. AMRO BioSciences is engaged into number of drugs for cancer. The clinical trial explores a drug (pegilodecakin) which is ongoing for the pancreatic cancer. The drug is into phase III of the clinical trials. The developments performed by the companies are helping the market to grow in the coming years.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone: +1-646-491-9876

Like it? Share it!


Shahbaz

About the Author

Shahbaz
Joined: September 26th, 2022
Articles Posted: 71

More by this author